Literature DB >> 16859431

Samarium for osteoblastic bone metastases and osteosarcoma.

Pete Anderson1.   

Abstract

Samarium-153 lexidronam (153Sm-EDTMP) is FDA approved for painful osteoblastic bone metastases that image on bone scan. 153Sm-EDTMP decay has a therapeutic beta-emission and a gamma-photon for bone scan imaging. Monitoring of osteosarcoma radiation treatment effectiveness was performed with bone, CT, MRI and PET/CT fusion imaging. Bone scan and PET/CT improved in 5 out of 9 and 16 out of 18 osteosarcoma sites, respectively. 153Sm-EDTMP targets multiple sites of disease, with a single administration. Side effects of 153Sm-EDTMP (0.5-2.5 mCi/kg) have been minimal and include transient thrombocytopenia and neutropenia. 153Sm-EDTMP can be combined with radiation therapy, bisphosphonates and/or chemotherapy to synergistically improve palliation. This article reviews the rationale, indications and monitoring of standard-dose samarium and investigational high-dose 153Sm-EDTMP treatment of cancer involving bone.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16859431     DOI： 10.1517/14656566.7.11.1475

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


  8 in total

Review 1.  Improving outcomes in difficult bone cancers using multimodality therapy, including radiation: physician and nursing perspectives.

Authors:  Pete Anderson; Maritza Salazar-Abshire
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

2.  Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.

Authors:  Vivek Subbiah; Pete M Anderson; Kalevi Kairemo; Kenneth Hess; Winston W Huh; Vinod Ravi; Najat C Daw; Neeta Somaiah; Joseph A Ludwig; Robert S Benjamin; Sant Chawla; David S Hong; Funda Meric-Bernstam; Gregory Ravizzini; Eugenie Kleinerman; Homer Macapinlac; Eric Rohren
Journal:  Clin Cancer Res       Date:  2019-02-07       Impact factor: 12.531

3.  A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver.

Authors:  James L Gulley; Ravi A Madan; Kwong-Yok Tsang; Philip M Arlen; Kevin Camphausen; Mahsa Mohebtash; Mitchell Kamrava; Jeffrey Schlom; Deborah Citrin
Journal:  Expert Opin Biol Ther       Date:  2011-08-28       Impact factor: 4.388

Review 4.  Radiopharmaceuticals for Treatment of Osteosarcoma.

Authors:  Peter M Anderson
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

5.  Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer.

Authors:  Sergio Ricci; Giuseppe Boni; Ilaria Pastina; Dario Genovesi; Claudia Cianci; Serena Chiacchio; Cinzia Orlandini; Mariano Grosso; Abedallatif Alsharif; Aldo Chioni; Samantha Di Donato; Francesco Francesca; Cesare Selli; Domenico Rubello; Giuliano Mariani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-23       Impact factor: 10.057

6.  Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP.

Authors:  Breelyn A Wilky; David M Loeb
Journal:  Clin Exp Pharmacol       Date:  2013-06

Review 7.  Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.

Authors:  Rocio K Rivera-Valentin; Limin Zhu; Dennis P M Hughes
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

Review 8.  Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer.

Authors:  Tyrillshall S T Damiana; Simone U Dalm
Journal:  Pharmaceutics       Date:  2021-05-07       Impact factor: 6.321
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.